 |
上海源葉生物科技有限公司
主營產品： S30260異硫氰酸胍,30259鹽酸胍,嗜熱菌蛋白酶 |
15
聯系電話
15921386130
公司信息
- 聯系人：
- 何小姐
- 電話：
- 86-021-61559134
- 手機：
- 15921386130
- 傳真：
- 86-021-55068248
- 地址：
- 上海市松江區長塔路465號6幢
- 郵編：
- 200433
- 網址：
- www.shyuanye.com
S80121
| 參考價 | 面議 |
具體成交價以合同協議為準
- 型號
- 品牌
- 廠商性質 生產商
- 所在地
更新時間：2025-05-16 07:34:23瀏覽次數：216
聯系我們時請說明是化工儀器網上看到的信息，謝謝!
- 提示：詳情請下載說明書。
- 產品描述： WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits mTORC1 and mTORC2.
- 靶點： mTORC1;mTORC2;mTOR:0.19 nM (IC50);PI3Kα:1.179 μM (IC50);PI3Kδ:2.38 μM (IC50);hSMG1:1.25 μM (IC50)
- 體內研究： A single i.v. administration of 50 mg/kg WYE-132 (WYE-125132) into tumor-bearing mice leads to suppression of P-S6K(T389) and P-AKT(S473) for at least 8 hours in PC3MM2, MDA361, HCT116, and HT29 tumors, whereas the steady-state level of P-AKT(T308) is not significantly reduced, indicating that the antitumor efficacy of WYE-132 under such dosing regimens reflects the suppression of mTOR rather than PI3K. Oral administration of WYE-132 causes dose-dependent tumor growth delay in the PI3K/mTOR- and HER2-hyperactive MDA361 tumors with significant antitumor activity at 5 mg/kg, which correlates with a suppression P-S6 and P-AKT(S473) but not P-AKT(T308). An optimal dose of 50 mg/kg WYE-132 induces a substantial regression of large MDA361 tumors. WYE-132 also causes a potent and substantial tumor growth delay in the PTEN-null U87MG glioma
- 參考文獻：
1. Yu K, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.Cancer Res. 2010 Jan 15;70(2):621-631.
- 溶解度： DMSO : 25 mg/mL (48.11 mM; Need ultrasonic)
- 保存條件： -20℃
- 配置溶液濃度參考：
1mg 5mg 10mg 1 mM 1.925 ml 9.623 ml 19.245 ml 5 mM 0.385 ml 1.925 ml 3.849 ml 10 mM 0.192 ml 0.962 ml 1.925 ml 50 mM 0.038 ml 0.192 ml 0.385 ml
- 注意：部分產品我司僅能提供部分信息，我司不保證所提供信息的性，僅供客戶參考交流研究之用。
